CONFERENCE DAY ONE

FEBRUARY 18, 2025

PART ONE: FIND YOUR FUTURE PARTNER

Bringing you a targeted and hyper-relevant partnership opportunity from the start, this opening section brings key buyers
together in a unique and unmissable format, to find you your next partner and route to more capital.

9.15-9.45: The Need in Neuroscience: Activity & Ambition for Deal Making during the Neuroscience Resurgence from
the Pharma Icebreaker

9.45- 11.00: Face-to-face matchmaking for protected networking time during the Pharma Matchmaking Roundtables to
qualify, hear feedback, and generate interest for the rest of the conference

11.45-12.15: Differences across investor strategies when evaluating early stage developments

7.30 am One-on-One PartneringTM portal meeting schedule starts. Grab a coffee and sit down with key contacts in the hour before the conference at bookable meeting spaces.

9:00 am Chair’s Opening Remarks

  • John Mayfield Senior Vice President - Business Development & Strategy, Flagship Pioneering

Strategic Priorities & Deal Trends for Future Collaborations & Investment in Neuroscience

9:05 am Pharma Icebreaker: The Need in Neuroscience: Activity & Ambition for Deal Making during the Neuroscience Resurgence

  • Jenny Laird Vice President & Global Head Search & Evaluation Neuroscience, Eli Lilly & Co.
  • John Mayfield Senior Vice President - Business Development & Strategy, Flagship Pioneering
  • Vidya Nadar Director, Search & Evaluation, Rare Neurological Disorders, Sanofi
  • Murali Gopalakrishnan Global Head of Neuroscience Search & Evaluation, Abbvie
  • Neel Desai Executive Director Business Development, Biogen

Synopsis

  • Sharing recent deal-making, current search and evaluation interests, and what pharma is looking for as a backdrop for conversations ahead
  • Discussing where future deal-making will lie for neurodegeneration and psychiatry distinctly to give insight into the before and landscape evolution

9:45 am Pharma Matchmaking Roundtables: Ensure you Connect

  • Neel Desai Executive Director Business Development, Biogen
  • Jenny Laird Vice President & Global Head Search & Evaluation Neuroscience, Eli Lilly & Co.
  • Murali Gopalakrishnan Global Head of Neuroscience Search & Evaluation, Abbvie
  • Vidya Nadar Director, Search & Evaluation, Rare Neurological Disorders, Sanofi

Synopsis

For interested parties, both pharma and attending biotech can select companies of interest for pre-organized rotations of 15-minute meetings across 1 hour. Meet face-to-face with priority companies, and benefit from introducing yourself to pharma you have not scheduled meetings with through the One-on-One PartneringTM portal early in the event.

11:00 pm Morning Break & One-on-One Networking

11:45 am Venture Panel:What Data Package is Exciting Enough to Invest in?

Synopsis

  • Where is each fund’s focus in Neuroscience? What is each fund excited about going forward regarding data or company type?
  • What does the panel see as newer and more interesting differentiation points?
  • When it comes to early innovation, what does the panel need to see to be excited about investing?

12:15 pm Lunch Break & One-on-One Partnering Networking

PART TWO: SHOWCASE YOUR SCIENCE

Designed to foster excitement and engagement in innovative companies, be part of back-to-back presentations to showcase your
pipeline, platform, and technologies to a room of aligned and qualified decision-makers.

Section One: The Right Modality for the Right Disease Marrying Breakthrough in Modalities with Breakthrough in Delivery, for Greater Duration of Action

1:20 pm Enabling Understanding of Target Modulation for Disease Modification

Synopsis

  • Modeling levels of protein modulation and restoration of protein function
  • Comparing phenotypes endogenously
  • Comparing relevant efficacy readouts

1:40 pm Leveraging the Power of Biotherapeutics to Address Unmet Medical Needs in CNS Diseases

  • Mathias Schmidt Chief Executive Officer, ArmaGen; Executive Fellow, JCR Pharmaceuticals Co Ltd

Synopsis

  • Evidencing how significant progress in the understanding of the biology of the bloodbrain-barrier has enabled biologics to become a viable modality for CNS diseases
  • Augmenting therapeutic efficacy of 2nd generation of approved Biologics Safe, through effective CNS shuttle platforms
  • Outlining key differences that exist in the delivery of protein therapeutics versus nucleic acid medicine into the brain

14:00 pm Afternoon Break & One-on-One Partnering Networking

3:20 pm Next Generation Splice Modulation Platform: Balancing Activity, Safety & Distribution of ASOs

  • Dan Elbaum Chief Scientific Officer, QurAlis Corp.

Synopsis

  • Contextualizing preRNA mis-splicing as a recurring theme in neurodegenerative diseases
  • Highlighting QurAlis’ FlexASO™ platform that enables the design and synthesis of splice-switching ASOs with enhanced potency, safety, and biodistribution properties
  • Discussing the platform generally and in the context of QurAlis’ discovery programs

3:40 pm Building on Clinical Progress & Challenges of PROTACs with Molecular Glues

Synopsis

  • Improving drug-like properties to drive efficacy
  • Increasing specificity of degradation and avoiding neo-substrate degradation
  • Increasing the cell type and tissue reach of degraders

4:00 pm Session Reserved for Aclipse Therapeutics

4.20 Aperitif Drinks Reception:

Enjoy an informal networking drinks reception with all attending and presenting companies to catch up with key stakeholders outside of the regular meeting, as a touchpoint between JPM and BIO in the conference calendar.

6:00 pm End of Day One Conference

VIEW AGENDA
BUY TICKET
To the top